Publikation:

Old Drugs with New Tricks : Paradigm in Drug Development Pipeline for Alzheimer’s Disease

Lade...
Vorschaubild

Dateien

Zu diesem Dokument gibt es keine Dateien.

Datum

2020

Autor:innen

Dalvi, Tanay
Dewangan, Bhaskar
Das, Rudradip
Rani, Jyoti
Shinde, Suchita D.
Vhora, Nazmina
Sahu, Bichismita

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

URI (zitierfähiger Link)
ArXiv-ID

Internationale Patentnummer

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Central Nervous System Agents in Medicinal Chemistry. Bentham Science Publishers. 2020, 20(3), pp. 157-176. ISSN 1871-5249. eISSN 1875-6166. Available under: doi: 10.2174/1871524920666201021164805

Zusammenfassung

The most common reason behind dementia is Alzheimer's disease (AD) and it is predicted to be the third lifethreatening disease apart from stroke and cancer for the geriatric population. Till now only four drugs are available in the market for symptomatic relief. The complex nature of disease pathophysiology and lack of concrete evidences of molecular targets are the major hurdles for developing new drug to treat AD. The the rate of attrition of many advanced drugs at clinical stages, makes the de novo discovery process very expensive. Alternatively, Drug Repurposing (DR) is an attractive tool to develop drugs for AD in a less tedious and economic way. Therefore, continuous efforts are being made to develop a new drug for AD by repursing old drugs through screening and data mining. For example, the survey in the drug pipeline for Phase III clinical trials (till February 2019) which has 27 candidates, and around half of the number are drugs which have already been approved for other indications. Although in the past the drug repurposing process for AD has been reviewed in the context of disease areas, molecular targets, there is no systematic review of repurposed drugs for AD from the recent drug development pipeline (2019-2020). In this manuscript, we are reviewing the clinical candidates for AD with emphasis on their development history including molecular targets and the relevance of the target for AD.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
540 Chemie

Schlagwörter

Alzheimer's Disease; Cancer; Diabetes; Drug pipeline; Drug repurposing; Drugs in clinical trials; Inflammation; Mechanism of action of drugs; and Neurodegeneration

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690DALVI, Tanay, Bhaskar DEWANGAN, Rudradip DAS, Jyoti RANI, Suchita D. SHINDE, Nazmina VHORA, Alok JAIN, Bichismita SAHU, 2020. Old Drugs with New Tricks : Paradigm in Drug Development Pipeline for Alzheimer’s Disease. In: Central Nervous System Agents in Medicinal Chemistry. Bentham Science Publishers. 2020, 20(3), pp. 157-176. ISSN 1871-5249. eISSN 1875-6166. Available under: doi: 10.2174/1871524920666201021164805
BibTex
@article{Dalvi2020-10-21Drugs-52874,
  year={2020},
  doi={10.2174/1871524920666201021164805},
  title={Old Drugs with New Tricks : Paradigm in Drug Development Pipeline for Alzheimer’s Disease},
  number={3},
  volume={20},
  issn={1871-5249},
  journal={Central Nervous System Agents in Medicinal Chemistry},
  pages={157--176},
  author={Dalvi, Tanay and Dewangan, Bhaskar and Das, Rudradip and Rani, Jyoti and Shinde, Suchita D. and Vhora, Nazmina and Jain, Alok and Sahu, Bichismita}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/52874">
    <dc:contributor>Rani, Jyoti</dc:contributor>
    <dc:creator>Shinde, Suchita D.</dc:creator>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/52874"/>
    <dc:contributor>Dewangan, Bhaskar</dc:contributor>
    <dcterms:title>Old Drugs with New Tricks : Paradigm in Drug Development Pipeline for Alzheimer’s Disease</dcterms:title>
    <dc:creator>Rani, Jyoti</dc:creator>
    <dc:creator>Das, Rudradip</dc:creator>
    <dc:contributor>Shinde, Suchita D.</dc:contributor>
    <dc:contributor>Das, Rudradip</dc:contributor>
    <dc:creator>Jain, Alok</dc:creator>
    <dcterms:issued>2020-10-21</dcterms:issued>
    <dc:language>eng</dc:language>
    <dc:creator>Sahu, Bichismita</dc:creator>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/29"/>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:contributor>Dalvi, Tanay</dc:contributor>
    <dc:contributor>Sahu, Bichismita</dc:contributor>
    <dc:rights>terms-of-use</dc:rights>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Dewangan, Bhaskar</dc:creator>
    <dc:creator>Dalvi, Tanay</dc:creator>
    <dc:contributor>Vhora, Nazmina</dc:contributor>
    <dc:creator>Vhora, Nazmina</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/29"/>
    <dcterms:abstract xml:lang="eng">The most common reason behind dementia is Alzheimer's disease (AD) and it is predicted to be the third lifethreatening disease apart from stroke and cancer for the geriatric population. Till now only four drugs are available in the market for symptomatic relief. The complex nature of disease pathophysiology and lack of concrete evidences of molecular targets are the major hurdles for developing new drug to treat AD. The the rate of attrition of many advanced drugs at clinical stages, makes the de novo discovery process very expensive. Alternatively, Drug Repurposing (DR) is an attractive tool to develop drugs for AD in a less tedious and economic way. Therefore, continuous efforts are being made to develop a new drug for AD by repursing old drugs through screening and data mining. For example, the survey in the drug pipeline for Phase III clinical trials (till February 2019) which has 27 candidates, and around half of the number are drugs which have already been approved for other indications. Although in the past the drug repurposing process for AD has been reviewed in the context of disease areas, molecular targets, there is no systematic review of repurposed drugs for AD from the recent drug development pipeline (2019-2020). In this manuscript, we are reviewing the clinical candidates for AD with emphasis on their development history including molecular targets and the relevance of the target for AD.</dcterms:abstract>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-02-17T10:51:46Z</dcterms:available>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-02-17T10:51:46Z</dc:date>
    <dc:contributor>Jain, Alok</dc:contributor>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Nein
Begutachtet
Ja
Diese Publikation teilen